celsion is a biopharmaceutical company dedicated to the research and development of innovative, targeted therapies that address unmet medical needs in oncology. with the recent acquisition of egen, inc., celsion has become a fully integrated company with an extensive, complementary, multi-phase clinical pipeline; platform technologies for the discovery of novel, nucleic acid-based immunotherapies and other anti-cancer dna/rna therapies; and expertise from bench to bedside.
Company profile
Ticker
IMNN
Exchange
Website
CEO
Michael Tardugno
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CELSION CORP, Celsion CORP, CHEUNG LABORATORIES INC
SEC CIK
Corporate docs
Subsidiaries
CLSN Laboratories, Inc. ...
IRS number
521256615
IMNN stock data
Latest filings (excl ownership)
8-K
IMUNON Reports Compliance with Nasdaq Listing Requirements
11 Apr 24
RW
Registration withdrawal request
10 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
IMUNON Reports 2023 Financial Results and Provides Business Update
28 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
18 Mar 24
8-K
IMUNON Announces Leadership Change
12 Mar 24
S-1/A
IPO registration (amended)
9 Feb 24
S-1/A
IPO registration (amended)
17 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Dec 23
S-1
IPO registration
20 Dec 23
Transcripts
IMNN
Earnings call transcript
2023 Q4
28 Mar 24
IMNN
Earnings call transcript
2023 Q3
14 Nov 23
IMNN
Earnings call transcript
2023 Q2
10 Aug 23
IMNN
Earnings call transcript
2023 Q1
11 May 23
IMNN
Earnings call transcript
2022 Q3
16 Nov 22
IMNN
Earnings call transcript
2022 Q2
15 Aug 22
IMNN
Earnings call transcript
2022 Q2
15 Aug 22
IMNN
Earnings call transcript
2022 Q1
16 May 22
IMNN
Earnings call transcript
2022 Q1
16 May 22
IMNN
Earnings call transcript
2021 Q4
31 Mar 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 12.88 mm | 12.88 mm | 12.88 mm | 12.88 mm | 12.88 mm | 12.88 mm |
Cash burn (monthly) | (no burn) | 1.67 mm | 1.30 mm | 1.83 mm | 1.49 mm | 1.69 mm |
Cash used (since last report) | n/a | 11.43 mm | 8.90 mm | 12.54 mm | 10.20 mm | 11.57 mm |
Cash remaining | n/a | 1.45 mm | 3.98 mm | 347.85 k | 2.69 mm | 1.32 mm |
Runway (months of cash) | n/a | 0.9 | 3.1 | 0.2 | 1.8 | 0.8 |
Institutional ownership, Q2 2023
62.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 0 |
Closed positions | 3 |
Increased positions | 5 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 425.14 mm |
Total shares | 5.83 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
FiveMore Fund | 2.75 mm | $3.77 mm |
Lincoln Park Capital Fund | 1.58 mm | $1.65 mm |
CVI Investments | 1.10 mm | $0.00 |
Vanguard | 121.85 k | $157.18 mm |
Renaissance Technologies | 74.01 k | $95.00 k |
BLK Blackrock | 67.16 k | $86.63 mm |
Citadel Advisors | 51.67 k | $66.66 mm |
Geode Capital Management | 48.93 k | $63.12 mm |
STT State Street | 14.30 k | $18.45 mm |
Susquehanna International | 10.86 k | $14.01 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Church Jeffrey Wayne | Stock Option Common Stock | Grant | Acquire A | No | No | 0.86 | 25,000 | 21.50 k | 120,950 |
15 Mar 24 | Khursheed Anwer | Stock Option Common Stock | Grant | Acquire A | No | No | 0.86 | 25,000 | 21.50 k | 110,688 |
15 Mar 24 | Tardugno Michael H | Stock Option Common Stock | Grant | Acquire A | No | No | 0.86 | 12,500 | 10.75 k | 228,346 |
15 Mar 24 | Fritz Frederick J. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.86 | 3,500 | 3.01 k | 33,599 |
15 Mar 24 | Braun Donald P | Option to purchase Imunon common stock Imunon, Inc. Common Stock | Grant | Acquire A | No | No | 0.86 | 3,500 | 3.01 k | 19,930 |
News
IMUNON Reports Compliance With Nasdaq Listing Requirements
11 Apr 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
5 Apr 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
2 Apr 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
2 Apr 24
Imunon Q4 EPS $(0.52) Beats $(2.30) Estimate
28 Mar 24